CONNAUGHTON BERNADETTE sold 7.9% of their position (4K shares) of HALOZYME THERAPEUTICS, INC. on the open market
Open‑market sale worth $294.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 9/2/2025ACC: 0001415889-25-023470
Director
Since Sep 2018
-4K
Net shares
Net seller
$294.7K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
4K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−100.00
Price / share
$71.71
Trade value
$7.17K
% of position
0.2%
9/2/2025
50.95K→50.85K
Common Stock
Direct
Shares
−2.98K
Price / share
$73.62
Trade value
$219.16K
% of position
5.9%
9/2/2025
50.85K→47.88K
Common Stock
Direct
Shares
−923.00
Price / share
$74.11
Trade value
$68.40K
% of position
1.9%
9/2/2025
47.88K→46.95K
Total
Net shares
−4K
Net value
-$294.74K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/2/2025 | S · Sale | −100.00 | $71.71 | $7.17K | 0.2% | 50.95K | 50.85K |
| Common Stock Direct | 9/2/2025 | S · Sale | −2.98K | $73.62 | $219.16K | 5.9% | 50.85K | 47.88K |
| Common Stock Direct | 9/2/2025 | S · Sale | −923.00 | $74.11 | $68.40K | 1.9% | 47.88K | 46.95K |
| Total | −4K | -$294.74K | ||||||
Derivative Transactions0
No derivative transactions reported